ABL Diagnostics Société anonyme (EPA:ABLD)
France flag France · Delayed Price · Currency is EUR
5.45
0.00 (0.00%)
Last updated: Jul 15, 2025

ABL Diagnostics Société anonyme Company Description

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally.

It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation system, and sanger sequencing reagents.

The company also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB.

It sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers.

The company was formerly known as Etablissements Fauvet Girel and changed its name to ABL Diagnostics Société anonyme in April 2022.

The company is based in Woippy, France. ABL Diagnostics Société anonyme is a subsidiary of Advanced Biological Laboratories (ABL) S.A.

ABL Diagnostics Société anonyme
CountryFrance
IndustryHealth Information Services
SectorHealthcare
Employees19
CEOChalom Sayada

Contact Details

Address:
72c, rue de Thionville
Woippy, 57140
France
Phone33 3 87 17 81 56
Websiteabldiagnostics.com

Stock Details

Ticker SymbolABLD
ExchangeEuronext Paris
Fiscal YearJanuary - December
Reporting CurrencyEUR
ISIN NumberFR001400AHX6
SIC Code9998

Key Executives

NamePosition
Dr. Chalom B. Sayada M.D., Ph.D.GM and Director
Ronan BoulmeDirector of Regulatory Affairs